Selective estrogen receptor modulators are advancing notably in treating hormone‐driven conditions, offering opportunities across oncology and women' ...

University of Cambridge-led trial shows significant improvement in outcomes for inherited, aggressive forms of breast cancerA ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Artificial intelligence (AI) technologies and machine learning (ML) algorithms are witnessing tremendous growth in immunology ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research’s global market analysis of nanotechnology in oncology.”Boston, June 05, 2025 (GLOBE NEWSWIRE) -- ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Raised over $12 million, thanks to the collective efforts of charitable partners, corporate sponsors, all 32 NHL Clubs and ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...